Physician profile
Baxter D Wellmon
NPI 1518007020
$19,534.15
in general payments reported to CMS, 2019-2025
57 companies · $2,848 in 2025
The $2,848 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,397 · 2020: $2,477 · 2021: $3,236 · 2022: $3,214 · 2023: $2,776 · 2024: $2,586 · 2025: $2,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,209 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,208.71 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,519.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $2,552.14 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Astrazeneca Pharmaceuticals LP | $1,700.13 | 2019-2025 | Farxiga, Fasenra, Airsupra |
| Abbvie INC. | $1,662.48 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $1,003.70 | 2019-2025 | Trelegy Ellipta, Pediarix, Bexsero |
| Pfizer INC. | $930.47 | 2019-2025 | |
| Lilly USA, LLC | $922.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.87 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $504.06 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Amgen INC. | $480.99 | 2019-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $471.87 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.66 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $418.68 | 2019-2024 | Xarelto, Spravato |
| Astellas Pharma US INC | $406.20 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $318.99 | 2019-2025 | Trintellix |
Show all 56 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baxter Wellmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.